Literature DB >> 30863616

The superstars of precision medicine-EGFR inhibitors in adjuvant treatment of lung cancer.

Jin Xia1,2, Wen-Zhao Zhong1,2, Yi-Long Wu1,2.   

Abstract

Entities:  

Year:  2019        PMID： 30863616      PMCID： PMC6384350          DOI： 10.21037/jtd.2018.12.72

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer-the more specific, the better?

Authors:  Elisabeth Smolle; Martin Pichler
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  Tumor recurrence after complete resection for non-small cell lung cancer.

Authors:  Matthew D Taylor; Alykhan S Nagji; Castigliano M Bhamidipati; Nicholas Theodosakis; Benjamin D Kozower; Christine L Lau; David R Jones
Journal:  Ann Thorac Surg       Date:  2012-04-26       Impact factor: 4.330

5.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Wilbur A Franklin; Rafal Dziadziuszko; Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Claire Watkins; Angela Flannery; Gillian Ellison; Emma Donald; Lucy Knight; Dinah Parums; Nicholas Botwood; Brian Holloway
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

Authors:  M Kimura; F Yasue; E Usami; S Kawachi; M Iwai; M Go; Y Ikeda; T Yoshimura
Journal:  Mol Clin Oncol       Date:  2018-05-30

8.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

9.  ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.

Authors:  Yi-Long Wu; Roy S Herbst; Helen Mann; Yuri Rukazenkov; Marcelo Marotti; Masahiro Tsuboi
Journal:  Clin Lung Cancer       Date:  2018-05-01       Impact factor: 4.785

10.  A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.

Authors:  Antonin Levy; Etienne Bardet; Benjamin Lacas; Jean-Pierre Pignon; Julien Adam; Ludovic Lacroix; Xavier Artignan; Pierre Verrelle; Cécile Le Péchoux
Journal:  Oncotarget       Date:  2017-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.